Nanobodies and their potential applications

Nanomedicine

Volumn 8, Issue 6, 2013, Pages 1013-1026

  Hassanzadeh Ghassabeh, Gholamreza ^a   Devoogdt, Nick ^a   De Pauw, Pieter ^a   Vincke, Cécile ^a   Muyldermans, Serge ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Camelidae; crystallization chaperone; deep sequencing; enzyme inhibitor; heavy chain only antibody; immune repertoire; intracellular delivery; nanobody; single domain antibody

Indexed keywords

CHAPERONE; NANOBODY; PROTEOME;

AMYLOIDOSIS; ARTIODACTYLA; BIOSENSOR; CANCER THERAPY; CELL SELECTION; CRYSTAL STRUCTURE; CRYSTALLIZATION; HUMAN; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; PHENOTYPE; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 84878714164     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.86     Document Type: Review

References (92)

1. Gill DS, Damle NK. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17(6), 653-658 (2006).
2. Hamers-Casterman C, Atarhouch T, Muyldermans S et al. Naturally-occurring antibodies devoid of light-chains. Nature 363(6428), 446-448 (1993).
3. Flajnik MF, Deschacht N, Muyldermans S. A Case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biology 9(8), e1001120 (2011).
4. De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. Devel. Comp. Immunol. 30(1-2), 187-198 (2006).
5. Cortez-Retamozo V, Backmann N, Senter PD et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64(8), 2853-2857 (2004).
6. Stijlemans B, Caljon G, Natesan SKA et al. High affinity nanobodies against the trypanosome brucei vsg are potent trypanolytic agents that block endocytosis. PLoS Pathogens 7(6), e1002072 (2011).
7. Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh- Ghassabeh G, Muyldermans S. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol. Biol. 907, 145-176 (2012).
8. Monegal A, Ami D, Martinelli C et al. Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng. Des. Sel. 22(4), 273-280 (2009).
9. Koide A, Tereshko V, Uysal S, Margalef K, Kossiakoff AA, Koide S. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar K-D of a single-domain antibody with a flat paratope. J. Mol. Biol. 373(4), 941-953 (2007).
10. De Genst E, Silence K, Decanniere K et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl Sci. USA 103(12), 4586-4591 (2006).
11. Davies J, Riechmann L. Camelising Human antibody fragments - NMR-studies on Vh domains. FEBS Letts 339(3), 285-290 (1994).
12. Vincke C, Loris R, Saerens D, Martinez Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284(5), 3273-3284 (2009).
13. Jahnichen S, Blanchetot C, Maussang D et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl Sci. USA 107(47), 20565-20570 (2010).
14. Koch-Nolte F, Reyelt J, Schoessow B et al. Single domain antibodies from llama effectively and specifically block T cell ecto ADP-ribosyltransferase ART2.2 in vivo. FASEB J. 21(13), 3490-3498 (2007).
15. Janssens R, Dekker S, Hendriks RW et al. Generation of heavy-chain-only antibodies in mice. Proc. Natl Sci. USA 103(41), 15130-15135 (2006).
16. Pellis M, Pardon E, Zolghadr K et al. A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch. Biochem. Biophys. 526(2), 114-123 (2012).
17. Reddy ST, Ge X, Miklos AE et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 28(9), 965-969 (2010).
18. Ravn U, Gueneau F, Baerlocher L et al. By passing in vitro screening-next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Res. 38(21), e193 (2010).
19. Hassanzadeh-Ghassabeh G, Saerens D, Muyldermans S. Generation of anti infectome/anti-proteome nanobodies. Methods Mol. Biol. 790, 239-259 (2011).
20. Abbady AQ, Al-Daoude A, Al-Mariri A, Zarkawi M, Muyldermans S. Chaperonin GroEL a Brucella immunodominant antigen identified using nanobody and MALDI-TOF-MS technologies. Vet. Immunol. Immunopathol. 146(3-4), 254-263 (2012).
21. Digiandomenico A, Warrener P, Hamilton M et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J. Exp. Med. 209(7), 1273-1287 (2012).
22. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat. Med. 7(11), 1249-1253 (2001).
23. Klooster R, Eman Mr, Le Duc Q et al. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression. J. Immunol. Meth. 342(1-2), 1-12 (2009).
24. De Genst E, Areskoug D, Decanniere K, Muyldermans S, Andersson K. Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. J. Biol. Chem. 277(33), 29897-29907 (2002).
25. Esvelt KM, Carlson JC, Liu DR. A system for the continuous directed evolution of biomolecules. Nature 472(7344), 499-503 (2011).
26. Van Den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22(6), 888-893 (2011).
27. McNaughton BR, Cronican JJ, Thompson DB, Liu DR. Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc. Natl Sci. USA 106(15), 6111-6116 (2009).
28. Blanco-Toribio A, Muyldermans S, Frankel G, Angel Fernandez L. Direct injection of functional single-domain antibodies from E. coli into human cells. PLoS ONE 5(12), e15227 (2010).
29. Verheesen P, Ten Haaft MR, Lindner N, Verrips CT, de Haard JJW. Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim. Biophys. Acta 1624(1-3), 21-28 (2003).
30. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell. Proteomics 7(2), 282-289 (2008).
31. Adams H, Brummelhuis W, Maassen B et al. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol. Bioeng. 104(1), 143-151 (2009).
32. Klooster R, Maassen BTH, Stam JC et al. Improved anti-IgG and HSA affinity ligands: Clinical application of VHH antibody technology. J. Immunol. Meth. 324(1-2), 1-12 (2007).
33. Loris R, Marianovsky I, Lah J et al. Crystal structure of the intrinsically flexible addiction antidote MazE. J. Biol. Chem. 278(30), 28252-28257 (2003).
34. Tereshko V, Uysal S, Koide A, Margalef K, Koide S, Kossiakoff AA. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and x ray phasing capabilities of a camelid single-domain antibody (V(H)H) scaffold. Protein Sci. 17(7), 1175-1187 (2008).
35. Baranova E, Fronzes R, Garcia-Pino A et al. SbsB structure and lattice reconstruction unveil Ca2+ triggered S layer assembly. Nature 487(7405), 119-122 (2012).
36. Rasmussen SGF, Choi H-J, Fung JJ et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469(7329), 175-180 (2011).
37. Koide S. Engineering of recombinant crystallization chaperones. Curr. Opin. Struct. Biol. 19, 449-457 (2009).
38. Dumoulin M, Last AM, Desmyter A et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424(6950), 783-788 (2003).
39. Domanska K, Vanderhaegen S, Srinivasan V et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta 2-microglobulin variant. Proc. Natl Sci. USA 108(4), 1314-1319 (2011).
40. Habicht G, Haupt C, Friedrich RP et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A beta protofibrils. Proc. Natl Sci. USA 104(49), 19232-19237 (2007).
41. Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr. Opin. Biotechnol. 22(6), 882-887 (2011).
42. Olichon A, Surrey T. Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli. J. Biol. Chem. 282(50), 36314-36320 (2007).
43. Ries J, Kaplan C, Platonova E, Eghlidi H, Ewers H. A simple, versatile method for GFP-based super-resolution microspcopy via nanobodies. Nat. Methods 9(6), 582-584 (2012).
44. Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeyen ME. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat. Biotechnol. 21(1), 77-80 (2003).
45. Tanaka T, Sewell H, Waters S, Phillips SEV, Rabbitts TH. Single domain intracellular antibodies from diverse libraries emphasizing dual functions of LMO2 protein interactions using a single VH domain. J. Biol. Chem. 286(5), 3707-3716 (2011).
46. De Clercq S, Zwaenepoel O, Martens E, Vandekerckhove J, Guillabert A, Gettemans J. Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation. Cell. Mol. Life Sci. 70, 909-922 (2013).
47. Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P. Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. J. Gen. Virol. 91, 643-652 (2010).
48. Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti synuclein intrabodies. MAbs 4(6), 686-693 (2012).
49. Caussinus E, Kanca O, Affolter M. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. Nat. Struct. Mol. Biol. 19(1), 117-121 (2012).
50. Sukhanova A, Even-Desrumeaux K, Kisserli A et al. Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomed. Nanotechnol. Biol. Med. 8(4), 516-525 (2012).
51. Pollithy A, Romer T, Lang C et al. Magnetosome expression of functional camelid antibody fragments (nanobodies) in magnetospirillum gryphiswaldense. Appl. Env. Microbiol. 77(17), 6165-6171 (2011).
52. Vaneycken I, D'huyvetter M, Hernot S et al. Immuno-imaging using nanobodies. Curr. Opin. Biotechnol. 22(6), 877-881 (2011).
53. Movahedi K, Schoonooghe S, Laoui D et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 72(16), 4165-4177 (2012).
54. Broisat A, Hernot S, Toczek J et al. Nanobodies targeting mouse/human vcam1 for the nuclear imaging of atherosclerotic lesions. Circ. Res. 110(7), 927-937 (2012).
55. Caljon G, Caveliers V, Lahoutte T et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br. J. Pharmacol. 165(7), 2341-2353 (2012).
56. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22(6), 868-876 (2011).
57. Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68(5), 1439-1454 (2005).
58. Harmsen MM, Van Solt CB, Fijten HPD, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 23(41), 4926-4934 (2005).
59. Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol. Cancer Ther. 7(8), 2288-2297 (2008).
60. Vugmeyster Y, Entrican CA, Joyce AP et al. Pharmacokinetic, biodistribution and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethyleen glycol). Bioconj. Chem. 23(7), 1452-1462 (2012).
61. Iqbal U, Trojahn U, Albaghdadi H et al. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br. J. Pharmacol. 160(4), 1016-1028 (2010).
62. Harrison RA, Cook DA, Renjifo C, Casewell NR, Currier RB, Wagstaff SC. Research strategies to improve snakebite treatment: challenges and progress. J. Proteomics 74(9), 1768-1780 (2011).
63. Bouhaouala-Zahar B, Ben Abderrazek R, Hmila I, Abidi N, Muyldermans S, El Ayeb M. Immunological aspects of scorpion toxins: current status and perspectives. Inflamm. Allergy Drug Targets 10(5), 358-368 (2011).
64. Hmila I, Saerens D, Ben Abderrazek R et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 24(9), 3479-3489 (2010).
65. Hmila I, Cosyns B, Tounsi H et al. Pre-clinical studies of toxin-specific nanobodies: evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. Toxicol. Appl. Pharmacol. 264(2), 222-231 (2012).
66. Wesolowski J, Alzogaray V, Reyelt J et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198(3), 157-174 (2009).
67. Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest. 40(3), 299-338 (2011).
68. Broersens K, Rousseau F, Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers Res. Ther. 2(4), 12 (2010).
69. Lafaye P, Achour I, England P, Duyckaerts C, Rougeon F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 46(4), 695-704 (2009).
70. De Genst E, Dobson CM. Nanobodies as structural probes of protein misfolding and fibril formation. Methods Mol. Biol. 911, 533-558 (2012).
71. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 15(14), 240-242 (2001).
72. Li T, Bourgeois JP, Celli S et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood- brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 26(10), 3969-3979 (2012).
73. Ulrichts H, Silence K, Schoolmeester A et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118(3), 757-765 (2011).
74. Coppieters K, Dreier T, Silence K et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 54(6), 1856-1866 (2006).
75. Roovers RC, Laeremans T, Huang L et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol. Immunother. 56(3), 303-317 (2007).
76. Roovers RC, Vosjan MJWD, Laeremans T et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int. J. Cancer 129(8), 2013-2024 (2011).
77. Goyvaerts C, Robays L, De Groeve K et al. Targeting lentiviral vectors to dendritic cells by the nanobody display technology. Human Gene Therapy 21(10), 1440-1441 (2012).
78. Hernot S, Unnikrishnan S, Du Z et al. Nanobody-coupled microbubbles as novel molecular tracer. J. Control. Release 158(2), 346-353 (2012).
79. Van de Broek B, Devoogdt N, D'Hollander A et al. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano 5(6), 4319-4328 (2011).
80. Altintas I, Kok RJ, Schiffelers RM. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur. J. Pharm. Sci. 45(4), 399-407 (2012).
81. Shishido T, Azumi Y, Nakanishi T et al. Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J. Biochem. 146(6), 867-874 (2009).
82. Talelli M, Rijcken CJF, Oliveira S et al. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. J. Control. Release 151(2), 183-192 (2011).
83. May C, Sapra P, Gerber H-P. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem. Pharmacol. 84(9), 1105-1112 (2012).
84. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69(12), 4941-4944 (2009).
85. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: clinical experience. Curr. Opin. Mol. Ther. 12(3), 340-349 (2010).
86. Saerens D, Hassanzadeh-Ghassabeh G, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8(5), 600-608 (2008).
87. Chames P, Baty D. Bispecific antibodies for cancer therapy. The light at the end of the tunnel? MAbs 1(6), 539-547 (2009).
88. Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr. Opin. Mol. Ther. 12(1), 55-63 (2010).
89. Baeuerle PA, Itin C. Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. Curr. Pharm. Biotechnol. 13(8), 1399-1408 (2012).
90. Bakhtiari SH, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaee MJ. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma 28(2), 85-92 (2009).
91. Crescendo. www.crescendo.com
92. Ablynx. www.ablynx.com